Lung adenocarcinoma
Conditions
Interventions
Observation group:None
Sponsors
Fuzhou University Affiliated Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Histopathologically confirmed primary lung adenocarcinoma after surgery; 2. No prior anti-tumor therapy before surgery (including chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.); 3. Aged >= 18 years, both genders; 4. Complete clinical and pathological data (including TNM stage, lymph node metastasis status, follow-up survival information, etc.); 5. Voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Presence of other malignant tumors (pathologically confirmed, excluding cured non-melanoma skin cancer or cervical carcinoma in situ); 2. Received neoadjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy before surgery; 3. Complicated with severe infection, autoimmune diseases, or major organ failure (e.g., heart, liver, kidney); 4. Pregnant or lactating women; 5. Incomplete clinical data or lost to follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NDRG1 protein expression;Ki-67 proliferation index;Total DRP1 protein level;Phosphorylated DRP1 (Ser616/Ser637) level;MFN1/2 protein level;OPA1 protein level;SUMO1/2/3-modified DRP1 level;DRP1 SUMOylation level; | — |
Countries
China
Contacts
Public ContactHuang Jianyuan
Fuzhou University Affiliated Provincial Hospital
Outcome results
None listed